SKYE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SKYE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Skye Bioscience's enterprise value is $259.71 Mil. Skye Bioscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-36.02 Mil. Therefore, Skye Bioscience's EV-to-EBITDA for today is -7.21.
The historical rank and industry rank for Skye Bioscience's EV-to-EBITDA or its related term are showing as below:
During the past 12 years, the highest EV-to-EBITDA of Skye Bioscience was 22322.75. The lowest was -67.44. And the median was -0.75.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-18), Skye Bioscience's stock price is $12.05. Skye Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.509. Therefore, Skye Bioscience's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Skye Bioscience's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skye Bioscience Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | 10.91 | -1.80 | -2.32 | -0.83 | -1.01 |
Skye Bioscience Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -0.69 | -0.99 | -1.17 | -1.01 | -10.00 |
For the Biotechnology subindustry, Skye Bioscience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Skye Bioscience's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Skye Bioscience's EV-to-EBITDA falls into.
Skye Bioscience's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 259.711 | / | -36.024 | |
= | -7.21 |
Skye Bioscience's current Enterprise Value is $259.71 Mil.
Skye Bioscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skye Bioscience (NAS:SKYE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Skye Bioscience's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 12.05 | / | -4.509 | |
= | At Loss |
Skye Bioscience's share price for today is $12.05.
Skye Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.509.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Skye Bioscience's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Punit Dhillon | director | 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
John D Diekman | 10 percent owner | C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Partners Vii, Llc | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Paul A. Grayson | director | 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
5am Ventures Vii, L.p. | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Kush Parmar | 10 percent owner | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Partners Ii, Llc | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Co-investors Ii Lp | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Versant Ventures Iii, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Scott M Rocklage | 10 percent owner | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Andrew J. Schwab | director, 10 percent owner | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Versant Side Fund Iii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
5am Ventures Ii Lp | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Versant Venture Capital Iii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Deborah H. Charych | director | 1001 17TH ST, SAN FRANCISCO CA 94107 |
From GuruFocus
By Marketwired Marketwired • 10-05-2021
By Marketwired Marketwired • 10-07-2021
By Marketwired Marketwired • 10-21-2021
By GuruFocusNews GuruFocusNews • 12-15-2021
By GuruFocusNews GuruFocusNews • 07-01-2022
By Marketwired Marketwired • 10-07-2021
By Marketwired Marketwired • 10-12-2021
By PurpleRose PurpleRose • 07-20-2022
By GuruFocusNews GuruFocusNews • 05-22-2022
By Stock market mentor Stock market mentor • 01-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.